生理药代动力学模型研究COVID-19细胞因子风暴对CYP3A药物药代动力学的影响
该研究利用生理药代动力学(PBPK)模型模拟炎症对CYP3A代谢药物药代动力学的影响,模型基于HIV感染者洛匹那韦/利托那韦(LPV/r)临床数据开发,并经COVID-19患者数据验证。模拟显示COVID-19患者LPV暴露量较HIV感染者高两倍,利托那韦暴露相当,细胞因子风暴使咪达唑仑暴露增加40%。提示COVID-19患者CYP3A代谢改变,使用窄治疗指数药物尤其联用强CYP3A抑制剂时需谨慎。
要点
- COVID-19细胞因子风暴可抑制CYP3A代谢,使咪达唑仑暴露增加40%。
- COVID-19患者LPV暴露较HIV感染者高两倍,利托那韦暴露相当。
- 窄治疗指数CYP3A底物联用强抑制剂时需警惕暴露升高。
核心结论
- COVID-19患者细胞因子释放增加可改变CYP3A代谢,模拟显示咪达唑仑暴露增加40%。
- 临床处方窄治疗指数药物尤其联用强CYP3A抑制剂时需谨慎。
研究设计与样本
- 基于HIV感染者临床数据开发LPV/r的PBPK模型,用半机制抑制模型实现IL-6对CYPs的抑制,并经COVID-19患者LPV/r治疗数据验证。
- 验证后模型模拟不同临床观察IL-6水平对LPV/r和咪达唑仑暴露的影响。
主要发现
- 临床观察的HIV感染者和COVID-19患者LPV/r浓度均落在模拟结果95%置信区间内,显示模型预测能力。
- 模拟显示COVID-19患者LPV暴露较HIV感染者高两倍,利托那韦暴露预测相当。
- COVID-19下不同IL-6水平对LPV/r药代动力学仅有边缘影响。
- 模拟显示细胞因子风暴使CYP3A模型底物咪达唑仑暴露增加40%。
临床怎么用
- COVID-19患者使用窄治疗指数CYP3A底物时,尤其联用强CYP3A抑制剂,应警惕暴露升高并加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with coronavirus disease 2019 (COVID-19) may experience a cytokine storm with elevated interleukin-6 (IL-6) levels in response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). IL-6 suppresses hepatic enzymes, including CYP3A; however, the effect on drug exposure and drug-drug interaction magnitudes of the cytokine storm and resulting elevated IL-6 levels have not been characterized in patients with COVID-19. We used physiologically-based pharmacokinetic (PBPK) modeling to simulate the effect of inflammation on the pharmacokinetics of CYP3A metabolized drugs. A PBPK model was developed for lopinavir boosted with ritonavir (LPV/r), using clinically observed data from people living with HIV (PLWH). The inhibition of CYPs by IL-6 was implemented by a semimechanistic suppression model and verified against clinical data from patients with COVID-19, treated with LPV/r. Subsequently, the verified model was used to simulate the effect of various clinically observed IL-6 levels on the exposure of LPV/r and midazolam, a CYP3A model drug. Clinically observed LPV/r concentrations in PLWH and patients with COVID-19 were predicted within the 95% confidence interval of the simulation results, demonstrating its predictive capability. Simulations indicated a twofold higher LPV exposure in patients with COVID-19 compared with PLWH, whereas ritonavir exposure was predicted to be comparable. Varying IL-6 levels under COVID-19 had only a marginal effect on LPV/r pharmacokinetics according to our model. Simulations showed that a cytokine storm increased the exposure of the CYP3A paradigm substrate midazolam by 40%. Our simulations suggest that CYP3A metabolism is altered in patients with COVID-19 having increased cytokine release. Caution is required when prescribing narrow therapeutic index drugs particularly in the presence of strong CYP3A inhibitors.
引用
- Stader F, Battegay M, Sendi P, et al. Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients. Clin Pharmacol Ther. 2021. PMID: 34496043. doi:10.1002/cpt.2402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。